News
Follow us on LinkedIn and never miss the latest updates.
How to fight obesity and other metabolic disorders—swimmingly
June 2022
This article by Nature Research describes EraCal differentiated phenotypic strategy to measure food intake, energy expenditure, among other phenotypes at scale targeting cardiometabolic diseases.
EraCal enters into Research Collaboration with Novo Nordisk
17. January 2022
Read the full press release here.
Greg Hamilton and Jean-Michel Cossery join EraCal as independent board members
30. December 2021
EraCal Therapeutics appoints Jean-Michel Cossery and Greg Hamilton to its Board of Directors. Thank you for your leadership.
EraCal selected to TOP Swiss Biotech Startups 2021
8. September 2021
EraCal selected to top 100 Swiss Startup in 2021 – position 34 this year. Thank you for all your support.
EraCal launches a program targeting a novel class of appetite-stimulants
25. March 2021
The University of Zurich and EraCal start a new joint-project by applying the zebrafish technology towards appetite-stimulants. The program is part of the Swiss Innovation Power framework led by Innosuisse.
EraCal expands operations and moves to Bio-Technopark Schlieren Zurich, Switzerland
1. February 2021
EraCal operates now at Wagistrasse 13, 8952 Schlieren, Switzerland
EraCal featured among Switzerland's promising startups
9. September 2020
EraCal selected to the top100 Swiss StartUps for the first time in 2020. Thank you for all your support.
Nature and Merck KGaA highlight EraCal’s effort towards a long-term obesity therapy
30. June 2020
Thank you for depicting the advantages of EraCal’s phenotypic platform to identify selective and potent appetite suppressors. We are honored to be selected as a Spinoff prize finalist.
EraCal is a member of the Swiss National Startup Team 2020
22. April 2020
The Swiss Life Science National Team selected EraCal for its 2020 class. Thank you for recognizing our entrepreneurial ambitions.
IMD and EraCal join forces
13. December 2019
EraCal selected as an entrepreneurial showcase for IMD‘s Executive MBA class 2020.
_edited.jpg)
EraCal closed oversubscribed seed round
16. October 2019
EraCal joins forces with Bernina BioInvest, Redalpine, Life Sciences Fund and private investors to bring first-in-class medicines to patients. We are very grateful for their support of EraCal’s innovative research strategy! This seed investment enables the preclinical development of Era-107, our lead appetite suppressor with remarkable in vivo potency and selectivity, and a platform expansion to new indications.
EraCal wins MIT life science angels award
28. August 2019
EraCal won the MIT life science angels award and enjoyed thrilling days in Boston. Thank you for recognizing our creative science strategy and our global mission!
EraCal is a »venture» finalist
16. May 2019
EraCal Therapeutics is among the top 10 in the “Health & Nutrition” vertical of the »venture» business plan competition 2019. »venture» is Switzerland’s leading startup contest for entrepreneurs with high-tech business ideas.
EraCal moves to Schlieren
1. April 2019
EraCal moves to the IncubatorLab at Wagisstrasse 12 in Schlieren, Zurich, one of the best European biotechnology research hubs.
EraCal wins venturekick
31. January 2019
The venturekick jury selected EraCal Therapeutics Ltd. as a top Swiss start-up. Thank you very much for your continuing support of our vision!
EraCal in the scientific news
31. October 2018
Articles in Science Advance and the news of the University of Zurich (English Deutsch) describe part of our drug discovery strategy and its power for translational research.